Mineralys Therapeutics reported cash from operations of -$32.53M and free cash flow of -$32.53M for the quarter ended Jun 2026, down 7.8% year over year. This cash flow statement covers 18 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||
| Net Income | -7.57M | -6.48M | -6.68M | -9.07M | -12.61M | -12.14M | -22.76M | -24.39M | -31.51M | -41.02M | -56.33M | -48.96M | -42.21M | -43.27M | -36.94M | -32.23M | -39.34M | -241.08M |
| Share-based Compensation | 0.02M | 0.03M | 0.19M | 0.22M | 0.75M | 1.28M | 1.58M | 1.46M | 2.19M | 2.87M | 3.14M | 3.13M | 3.65M | 4.55M | 5.84M | 5.29M | 6.55M | 7.36M |
| Change in Interest Receivables | 0.27M | 0.17M | 0.22M | -0.30M | -0.12M | -0.18M | -0.02M | -0.10M | -0.05M | 0.05M | -0.01M | 0.18M | -0.29M | -0.05M | ||||
| Cash from Operations | -6.58M | -5.47M | -6.99M | -10.19M | -12.78M | -20.39M | -19.03M | -28.98M | -19.14M | -30.15M | -50.19M | -66.84M | -45.49M | -30.17M | -28.87M | -37.89M | -39.50M | -32.53M |
| Depreciation, Depletion & Amortization | ||||||||||||||||||
| Amortizatization of Intangibles | 0.24M | 0.41M | 0.85M | 1.98M | 1.96M | 2.07M | 2.51M | 2.85M | 2.71M | 1.34M | 1.05M | 2.23M | 2.40M | 4.21M | 4.62M | 4.64M | ||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M | ||||||||
| Change in Working Capital | ||||||||||||||||||
| Change in Accured Expenses | 0.86M | 1.03M | 0.27M | 0.85M | 1.91M | -3.77M | 7.34M | -3.06M | 8.40M | 9.47M | 2.96M | -16.67M | -1.55M | 9.07M | 1.03M | -8.13M | -0.40M | 3.67M |
| Other Working Capital Changes | -0.11M | 0.05M | 0.53M | 1.77M | 1.70M | 3.60M | 3.00M | 1.22M | -4.16M | -1.18M | -2.73M | 3.13M | 4.40M | -1.74M | -3.56M | -1.57M | 1.95M | -1.96M |
| Investing Activities | ||||||||||||||||||
| Capital Expenditures | 0.06M | 0.04M | 0.01M | |||||||||||||||
| Change in Acquisitions & Divestments | 50.00M | 22.50M | 40.00M | 60.00M | 65.00M | 67.50M | 135.00M | 138.50M | 147.50M | 35.00M | 75.00M | 150.00M | 165.00M | 302.50M | 325.00M | |||
| Cash from Investing Activities | -71.76M | 50.00M | -140.25M | -16.14M | 4.01M | -8.09M | -55.95M | 7.74M | 79.61M | 83.57M | -92.88M | -42.88M | -150.51M | -103.49M | -44.94M | -185.22M | ||
| Financing Activities | ||||||||||||||||||
| Other financing activities | -1.63M | 203.57M | -0.58M | 116.12M | -0.06M | 0.12M | 1.08M | 6.62M | 4.96M | 4.05M | 2.60M | |||||||
| Change in Capital Stock | ||||||||||||||||||
| Net Equity Issued and Repurchased | 12.00M | -12.00M | -0.56M | 118.22M | 203.57M | -0.58M | -202.99M | 189.17M | -0.29M | 81.32M | -0.32M | 20.22M | 123.68M | |||||
| Misc. | ||||||||||||||||||
| Cash from Financing Activities | 12.00M | 117.65M | -0.56M | -1.07M | 203.57M | -0.58M | 0.18M | 0.07M | 116.20M | -0.15M | -0.00M | 0.09M | 189.28M | 9.83M | 295.19M | 96.70M | 24.27M | 243.26M |
| Change in Cash | 5.42M | 112.18M | -79.31M | 38.75M | 50.55M | -37.11M | -14.84M | -37.00M | 41.11M | -22.56M | 29.42M | 16.82M | 50.92M | -63.22M | 115.81M | -44.68M | -60.14M | 25.49M |
| Free Cash Flow | -6.58M | -5.47M | -6.99M | -10.19M | -12.78M | -20.39M | -19.03M | -28.98M | -19.20M | -30.15M | -50.22M | -66.84M | -45.49M | -30.17M | -28.87M | -37.90M | -39.50M | -32.53M |
| Net Cash Flow | 5.42M | 112.18M | -79.31M | 38.75M | 50.55M | -37.11M | -14.84M | -37.00M | 41.11M | -22.56M | 29.42M | 16.82M | 50.92M | -63.22M | 115.81M | -44.68M | -60.17M | 25.52M |